In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Elan Corporation

http://www.elan.com

Latest From Elan Corporation

Otsuka Expands Ocular Gene Therapy Interests Through ShapeTX Deal

Otsuka steps into the ocular gene therapy field through a technology licensing deal worth up to $1.5bn with ShapeTX, which in turn further expands the US firm's global reach following a $3bn collaboration with Roche. 

Gene Therapy Deals

Biocon: Slow Humira Biosimilar Uptake But Payer Landscape Evolving

Biocon bets on dual pricing strategy in the US amid a “more gradual” than expected uptake of biosimilar adalimumab but emphasizes that payer positions aren’t “definitive” yet.

Biosimilars Strategy

Biocon: Slow Humira Biosimilar Uptake But Payer Landscape Evolving

Biocon bets on dual pricing strategy in the US amid a “more gradual” than expected uptake of biosimilar adalimumab but emphasizes that payer positions aren’t “definitive” yet.

Commercial Biosimilars

Organon Welcomes Prospect Of Interchangeability ‘Boost’ – But Pricing Still Key

Organon’s CEO Kevin Ali talked at length about the company’s launch of its Hadlima biosimilar version of Humira in the US during the company’s Q2 earnings call, following recent news it was looking to file for an interchangeability designation.

Biosimilars Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Onclave Therapeutics Limited
UsernamePublicRestriction

Register